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Abstract 
Background: In 2019 a literature review indicated that more than half of people who try to 
come off antidepressants experience withdrawal effects. Both NICE guidelines and the Royal 
College of Psychiatrists updated their positions in line with that review, and Public Health 
England published a 152-page report called Dependence and withdrawal associated with 
some prescribed medicines: an evidence review. The report made several recommendations 
relevant to GP practice. 
Method: In order to facilitate implementation of these recommendations an online survey 
was designed to explore UK GPs’ experiences, opinions, knowledge and needs in relation to 
depression, antidepressants, and withdrawal. 66 GPs had completed the survey when 
COVID-19 occurred. 
Results:  In keeping with previous findings, this small sample of GPs had a predominantly 
psycho-social perspective on the causes of, and treatments for, depression. They broadly 
considered antidepressants effective for moderate/severe depression and ineffective for 
minimal/mild depression, for which they preferred psychological therapies and social 
prescribing. There was a marked lack of consistency in GPs’ knowledge about the incidence 
and duration of withdrawal effects. Only a minority (29%) felt their knowledge about 
withdrawal was ‘adequate’ and fewer (17%) believed this about their ‘Ability to distinguish 
between withdrawal effects and return of the original problem (eg depression)’. Two thirds 
(68%) would like more training on these matters. 
A Survey of UK General Practitioners about Depression, Antidepressants 
and Withdrawal:  
Implementing the 2019 Public Health England Report 
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Conclusion: It is hoped that even this small sample will be helpful when designing, and 
seeking funding for, GP training programmes, and when implementing the PHE 
recommendations for support services, based in the primary care system, for the millions of 
people contemplating or initiating withdrawal from antidepressants every year in the UK.  
 
 
Introduction 
Annual antidepressant prescribing in the U.K. has doubled over the past ten years. Over a 
twelve month period  between 2017 and 2018, 7.3 million adults (17% of the adult 
population) were prescribed ADs in England alone; the rates for women, older people and 
people living in deprived areas were even higher.1 In the U.S.A. 8% of the population aged 
over 12 used ADs in any given month, between 1999-2002, increasing to 13% (37 million 
adults) by 2011-2014.2  High prescription rates also occur in Australia, Belgium, Canada, 
Iceland, Portugal and Sweden.3 
 
These continual increases occur despite significant concerns about efficacy and safety. A 
recent network meta-analysis4 reported small benefits compared with placebo, but the trials 
involved had multiple methodological flaws, with 82% rated as moderate or high risk of bias. 
It has long been established that less than half of trials find ADs superior to placebo.5,6 This 
lack of difference between ADs and placebos is particularly frequent in properly blinded, non 
industry-funded studies.7,8  One meta-analysis found that ‘the overall effect of new-generation 
antidepressant medications is below recommended criteria for clinical significance’ with 
benefit compared to placebo only for a tiny minority of recipients ‘at the upper end of the 
very severely depressed category’.9 Another meta-analysis, of 131 placebo-controlled trials, 
concluded that the overall effect size does not reach “clinical significance” and argued that 
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‘The harmful effects of SSRIs versus placebo for major depressive disorder seem to outweigh 
any potential small beneficial effects’.10  
 
High rates of adverse effects have been identified, originally in the biological domain, 
including nausea, impotence, insomnia, diarrhoea, dry mouth, dyspepsia, and sweating,11-13 
but more recently also in the personal and interpersonal domains, including emotional 
numbing, feeling not like oneself , agitation, reduction in positive feelings, caring less about 
others, and suicidality.14-17 
 
In this context, attempts to understand the perpetually increasing prescription rates began to 
focus on increases in repeat prescriptions. For example, UK data on 189,851 GP patients 
revealed that a doubling of prescribing over eight years was explained not by increases in 
new prescriptions but a doubling of the number of prescriptions per patient.18 
 
Such findings raised the issue of the withdrawal effects of antidepressants, until recently a 
somewhat taboo topic. In 2018 guidelines from the U.K National Institute for Health and 
Care Excellence (NICE) stated that antidepressant withdrawal symptoms ‘are usually mild 
and self-limiting over about 1 week, but can be severe, particularly if the drug is stopped 
abruptly’.19  Meanwhile U.S. guidelines claim that symptoms ‘typically resolve without 
specific treatment over 1–2 weeks’.20  Three recent systematic reviews have, however, 
indicated that  these are  gross underestimates.21-23 
 
The most recent of the three reviews21was undertaken for the All Party Parliamentary Group 
for Prescribed Drug Dependence in the UK, to inform an enquiry by Public Health England.1 
Fourteen studies found that withdrawal incidence ranged from 27% to 86%, with a weighted 
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average of 56%. Only four studies assessed severity; they produced a weighted average of 
46% of those experiencing withdrawal effects endorsing the most extreme severity rating on 
offer. Seven of the ten studies reported duration; they found that a significant proportion of 
people experiencing withdrawal do so for much longer than two weeks, and that it is not 
uncommon for it to last for several months or, more rarely, years. The reviewers1 concluded: 
 
‘We recommend that U.K. and U.S.A. guidelines on antidepressant withdrawal be 
urgently updated as they are clearly at variance with the evidence on the incidence, 
severity and duration of antidepressant withdrawal, and are probably leading to the 
widespread misdiagnosing of withdrawal, the consequent lengthening of 
antidepressant use, much unnecessary antidepressant prescribing and higher rates of 
antidepressant prescriptions overall. We also recommend that prescribers fully inform 
patients about the possibility of withdrawal effects.’ 
 
In May the RCPsych published an updated, evidence-based ‘Position statement on depression 
and antidepressants’,24 including: 
 
‘Discontinuation of antidepressants should involve the dosage being tapered or slowly 
decreased to reduce the risk of distressing symptoms, which may occur over several 
months. ….. The use of antidepressants should always be underpinned by a discussion 
about the potential level of benefits and harms, including withdrawal.’ 
 
In September, Public Health England published its 152 page document entitled ‘Dependence 
and withdrawal associated with some prescribed medications: An evidence review’.1 Having 
meticulously documented the extent of the problem it made a range of important 
recommendations, including for services to assist people coming off antidepressants and other 
psychiatric drugs, better research and more accurate national guidelines.   
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In October NICE updated its guidelines25 in line with the 2019 Davies and Read review, 
recommending that doctors:  
 
‘Advise people taking antidepressant medication that if they stop taking it abruptly, 
miss doses or do not take a full dose, they may have discontinuation symptoms such 
as: restlessness, problems sleeping, unsteadiness, sweating, abdominal symptoms, 
altered sensations (for example electric shock sensations in the head), altered feelings 
(for example irritability, anxiety or confusion). Explain that whilst the withdrawal 
symptoms which arise when stopping or reducing antidepressants can be mild and 
self-limiting, there is substantial variation in people’s experience, with symptoms 
lasting much longer (sometimes months or more) and being more severe for some 
patients.’26 
 
Among the many evidence-based recommendations in the PHE report1 was: 
‘GPs develop their knowledge of, and competence to identify, assess and respond to, 
dependence or withdrawal associated with some medicines and the support needs of 
people experiencing problems with withdrawal or dependence.’ 
 
The current study was designed to assess GPs’ experiences, knowledge, views, and needs 
(see Methods), so as to help effectively target efforts to implement this recommendation, in 
relation to antidepressants. 
 
Methods 
The study was approved by the University of East London’s Research Ethics Committee 
(Application ID: ETH1920-0048). 
 
An online questionnaire was designed, based primarily on the research literature discussed 
above,1,4-11,18-23 and later,28-35,42-45 in order to address UK GPs’ beliefs, knowledge and needs 
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in relation to antidepressants in general and withdrawal therefrom in particular. Questions 
were also asked about what GPs’ think cause depression and about the influence of drug 
companies.  Most questions generated quantitative data from multiple choice questions, but 
several generated qualitative data via open ended questions (including an ‘other’ option after 
some multiple-choice questions). 
 
The questionnaire was trialled on three GPs, and minor amendments made. The British 
Medical Journal published an article announcing the launch of the study, in February 2020.27 
The survey was also advertised on social media, including the ‘Resilient GP’ facebook group. 
When the COVID-19 pandemic occurred, participation ceased. It was subsequently decided 
to publish the findings despite the small sample size, with clear statements about the obvious 
limitations involved.   
 
Data analysis 
Quantitative data are presented as descriptive statistics (percentages etc.) without analysis by 
demographics, due to small numbers. Responses to open questions, were reported in terms of 
numbers of similar/identical responses.  
 
Results 
Sample characteristics 
Between February 7th and March 10, 2020, 66 GPs completed the survey, although three left 
some of the questions unanswered towards the end of the survey (see Tables 3,4,6,8). Of 
these 66, 46 (70%) were women. The average age of the sample was 48.9 years (SD 10.3) 
and they had worked as GPs for an average of 18.2 years (SD 10.9). Almost all (97%) 
worked in England, with one each from Scotland and Wales. 
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When asked to estimate how many of their patients ‘present with mood/depressive 
symptoms’ 26 (39%) ticked ’21-30%’, followed by 17 (26%) ticking ’11-20%’ and nine 
(14%) who estimated ’31-40%’. 
 
Causal beliefs 
The GPs were asked: ‘What do you think are the relative contributions of bio-genetic causes 
(e.g. chemical imbalance, genetic predisposition) vs social causes (e.g. stressful/traumatic 
events, loss etc.) for depression?’ The majority (53; 80%) felt that social causes contributed 
more than bio-genetic causes. The ratio most commonly endorsed (19; 29%) was ‘Bio 30% - 
Soc 70%; followed by ‘Bio 20 – Soc 80% (17; 26%). The most strongly endorsed specific 
causal factors were ‘Child abuse or neglect’ and ‘Violence/rape in adulthood’, and the least 
commonly endorsed were ‘Genetic predisposition’ and ‘chemical imbalance’ (see Table 1). 
 
Table 1. Which factors are ‘causes of depression’? 
 
n = 66 
 
Strongly 
Agree 
[1] 
 
 
Agree 
[2] 
Nether 
agree nor 
disagree 
[3] 
 
 
Disagree 
[4] 
 
Strongly 
Disagree 
[5] 
 
 
Mean 
Child abuse or neglect 86% 14%    1.14 
Violence/rape in 
adulthood 
82% 18%    1.18 
Other childhood 
adversities 
80% 20%    1.20 
Isolation/loneliness 79% 21%    1.21 
Drug/alcohol abuse 79% 18% 3%   1.24 
Family stress 73% 26% 2%   1.29 
Financial problems 71% 18% 2%   1.30 
Relationship problems 64% 36%    1.36 
Loss of loved one 67% 29% 5%   1.38 
Work stress 64% 35% 2%   1.38 
Medical conditions 58% 41% 2%   1.44 
Genetic predisposition 45% 36% 11% 5% 3% 1.83 
Chemical Imbalance 23% 54% 8% 11% 5% 2.18 
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24 participants added 28 ‘other’ causes. The only causes mentioned by more than one GP 
were social media – 3; personal characteristics – 3 (‘poor coping skills’, ‘low resilience’, 
‘personality traits’); and loss of control – 2 (e.g. ‘lack of control over many aspects of life eg 
poor housing, bad environment, high crime area etc.). 
 
Perceived efficacy 
Table 2 shows that the GPs thought antidepressants were far more effective for 
‘moderate/severe’ depression than for ‘minimal/mild’ depression; but only very slightly more 
effective in the first year of treatment than thereafter.  
 
Table 2. Perceived efficacy of antidepressants in various circumstances 
 
n = 65 
Very 
effective 
[1] 
Somewhat 
effective 
[2] 
Slightly 
effective 
[3] 
Not at all 
effective 
[4] 
Mean 
‘minimal/mild 
depression’ 
5% 28% 37% 31% 2.94 
‘moderate/severe 
depression’ 
25% 68% 5% 3% 1.86 
      
‘short-term treatment 
of depression 
(less than a year)’ 
29% 48% 15% 8% 2.02 
‘long-term treatment 
of depression 
(a year or more)’ 
15% 62% 17% 6% 2.14 
 
 
Information sources 
The most commonly endorsed responses to ’Which of the following have you used in the past 
12 months to inform your decisions about the treatment of depression?’ were British National 
Formulary (76%) and NICE Guidelines (71%), followed by Research Articles/Reviews 
(33%), Maudsley Prescribing Guide lines (27%) and Training Programme (27%). None 
endorsed ‘Drug Company Reps’ or ‘Other Drug Company Information’. Half of the 
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participants (33) cited 38 ‘other’ information sources, most commonly: local 
presentations/trainings (9); discussions with psychiatrists/mental health team (8); my own 
experience/learning from patients (6); and local guidelines (4).   
 
Of the 60 who answered the question about contact with drug company reps, 83% reported no 
contacts in the past year, 8% reported one contact and 8% reported between two and 14 
contacts. Of those with at least one contact 78% reported that their clinical practice was ‘not 
all’ influenced, 17% ticked ‘a little’ and 5% ticked ‘a moderate amount. Overall, only 4 GPs 
(7%) acknowledged being influenced. However, when asked how much other GPs were 
influenced, they reported that 82% of their colleagues had been influenced, with 25% ‘a 
moderate amount’ and 5% ‘a lot’.  
 
Clinical practice 
When asked ‘On average how long are you able to spend with a patient in the session at 
which you first prescribe antidepressants?’ most (69%) ticked ’10-20 minutes’; 23% ticked 
‘Less than 10 minutes’; and 8% ‘21–30 minutes.’ None ticked ‘31–45 minutes’ or ‘ More 
than 45 minutes’. 
 
Table 3 records that the most preferred of ten treatment options for ‘minimal/mild’ 
depression were: recommend self-referral to IAPT; social prescribing; and active monitoring; 
with antidepressants the 7th most endorsed option. For ‘moderate/severe’ depression 
antidepressants were the most preferred option, followed by referral to IAPT and social 
prescribing, with active monitoring relegated to 9th position. Referral to a psychiatrist was 
10th (last) for ‘minimal/mild and 8thfor moderate/severe. 
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‘Other’ treatments used by more than one GP, for minimal/mild depression, were 
mindfulness/meditation/yoga (3) and socialising (3). For moderate/severe depression some 
GPs also addressed work issues (3) and used crisis/support numbers (2).  
 
Of the 62 GPs who responded to the statement ‘Talking therapies should be as accessible as 
pharmacological treatments for depression’, 93% strongly agreed, 5% agreed and 2% (one 
GP) had no opinion.  
 
The GPs were asked ‘When discussing possible prescribing of antidepressants, how often do 
you inform patients of the possibility of withdrawal effects when reducing or coming off?’ Of 
the 63 who responded, 52% ticked ‘Always’, 25% ticked ‘Most of the time’, 14% ‘About half 
the time’, 5% ‘Occasionally’ and 3% ‘Never’. 
 
Participants were also asked ‘After patients have been on antidepressants for 3 months, 
approximately how often do you initiate discussion about when to come off them?’ The most 
frequently endorsed of the five options were ‘every 3 months’ (36%) and ‘every 6 months’ 
(36%), followed by ‘once a year’ (17%), once a month (11%) and ‘never’ (3%). 
 
Table 3. Treatment approaches used for ‘minimal/mild’ depression 
 
n = 63 
 
Never 
[1] 
Some- 
times 
[2] 
About half 
the time 
[3] 
Most of 
the 
time [4] 
 
Always 
[5] 
Mean 
Recommend self-referral to 
IAPT (Improving Access to 
Psychological Treatments) 
6% 14% 19% 38% 22% 3.56 
Social prescribing (exercise, 
nutrition, social activity, self-
help books etc.) 
3% 21% 17% 46% 13% 3.44 
Active monitoring/Watchful 
waiting 
2% 25% 25% 41% 6% 3.25 
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Refer to 
counsellor/psychotherapist/psyc
hologist 
6% 41% 22% 22% 8% 2.84 
Refer to computerised CBT 
(eg ‘Beating the Blues’) 
25% 44% 13% 14% 3% 2.25 
Provide psychological 
intervention yourself 
30% 43% 8% 14% 5% 2.21 
Prescription for antidepressant 
 
14% 71% 13% 2% 0% 2.02 
Refer to mental health services 
 
44% 38% 13% 2% 3% 1.81 
Refer to in-house mental health 
staff 
63% 24% 8% 3% 2% 1.56 
Refer to psychiatrist 
 
76% 19% 3% 0% 2% 1.32 
 
 
Table 4. Treatment approaches used for ‘moderate/severe’ depression  
 
n = 63 
 
Never 
[1] 
Some- 
times 
[2] 
About 
half the 
time [3] 
Most of 
the time 
[4] 
 
Always 
[5] 
 
Mean 
Prescription for antidepressant 
 
0% 9% 21% 62% 8% 3.68 
Recommend self-referral to 
IAPT (Improving Access to 
Psychological Treatments) 
13% 16% 11% 30% 30% 3.49 
Social prescribing (exercise, 
nutrition, social activity, self-
help books etc.) 
   6%  21% 19% 29% 25% 3.46 
Refer to counsellor/ 
psychotherapist/psychologist 
5% 29% 19% 31% 16% 3.24 
Refer to mental health services 
 
7% 52% 21% 15% 5% 2.59 
Provide psychological 
intervention yourself 
37% 33% 8% 13% 9% 2.25 
Refer to computerised CBT  
   (eg ‘Beating the Blues’) 
37% 40% 11% 6% 6% 2.06 
Refer to psychiatrist 
 
18% 63% 14% 5% 0% 2.06 
Active monitoring/Watchful 
waiting) 
33% 54% 5% 5% 3% 1.90 
Refer to in-house mental health 
staff 
63% 14% 14% 6% 2% 1.69 
 
 
Withdrawal: beliefs, knowledge and training needs 
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Table 5 reports the GPs’ estimates of how many people are ‘likely to experience withdrawal’ 
after being on antidepressants for three different time periods. Regardless of the time period, 
about one in four GPs (27%, 24%, 24%) believe that withdrawal effects are experienced by 
no more than 10%. Forty percent of the GPS thought that even after being on antidepressants 
for three years withdrawal is experienced by no more than 30% of their patients. 
 
There was a broad range of responses to ‘What percentage of patients can come off 
antidepressants within two months successfully?’ (see Table 6). There was a similar lack of 
consensus when asked ‘What % need very small decreases in antidepressant dosages over 
many months to come off them successfully’. 
 
Table 7 shows that just over half of the GPs thought their knowledge about withdrawal 
effects and their ability to distinguish withdrawal from relapse was ‘somewhat adequate’. 
Perhaps the most important finding of this study is that the majority (68%) said they would 
like more training or information. When asked what kind of training or information, 35 
provided 47 suggestions. In terms of content, six wanted 
guidelines/protocol/flowchart/strategies on how to wean patients off, and three wanted 
information about the withdrawal effects, including what they were, incidence and 
differences between antidepressants. In terms of process, 17 wanted some form of online 
training (e-learning, webinar) and eight wanted a local, face-to-face meeting/training. session. 
 
Table 5. GPs’ estimates of how many people are likely to experience withdrawal effects after 
being on antidepressants for various periods of time (n = 63) 
% of patients thought 
to experience 
withdrawal 
After  
3 months 
After  
1 year 
After  
3 years 
0 5% 3% 6% 
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1-10% 22% 21% 18% 
11-20% 21% 14% 5% 
21-30% 17% 9% 11% 
31-40% 8% 3% 11% 
41-50% 8% 19% 6% 
51-60% 5% 13% 5% 
61-70% 3% 8% 8% 
71-80% 11% 3% 10% 
81-90% - 5% 10% 
91-100% - 2% 11% 
 
 
Table 6. Length of time thought necessary for successful withdrawal. 
n = 63 
 
% of patients 
What % ‘can come off 
antidepressants successfully 
within two months’ 
What % ‘need very small decreases in 
antidepressant dosages over many 
months to come off them successfully’ 
0 3% 2% 
1-10% 9% 19% 
11-20% 8% 16% 
21-30% 9% 9% 
31-40% 6% 8% 
41-50% 19% 11% 
51-60% 5% 9% 
61-70% 11% 5% 
71-80% 21% 9% 
81-90% 6% 6% 
91-100% 2% 5% 
 
 
Table 7. Knowledge and training needs 
n = 66 Adequate Somewhat 
Adequate 
Not 
sure 
Somewhat 
Inadequate 
Inadequate 
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‘Knowledge about the 
withdrawal effects of 
antidepressants?’ 
 
29% 
 
54% 
 
11% 
 
5% 
 
2% 
‘Ability to distinguish 
between withdrawal effects 
and return of the original 
problem (eg depression)’ 
 
14% 
 
56% 
 
19% 
 
8% 
 
3% 
      
‘Would you like more 
training or information 
about the withdrawal effects 
of antidepressants?’ 
 YES 
68% 
 
16% 
NO 
16% 
 
 
 
Prescription rates 
The most endorsed of 13 factors explaining the increasing rates of prescribing were ‘Cuts to 
social services, benefits, etc.’ and ‘People are less embarrassed about saying they are 
depressed’ (see Table 8). The least endorsed was ‘Antidepressants are the best treatment’. 
Twenty-one GPs offered 32 other factors, including patient expectations (5), need for quick 
fix/magic pill (4), austerity (3), time-pressured lives (3), drug company pressure and 
misinformation (2), and limited mental health services (2).The majority (83%) think the 
prescribing rate is too high. 
 
Table 8. ‘Factors contributing to prescription rates of antidepressants increasing annually for 
the past 20 years’ 
 
 
n = 63 
 
Strongly 
Agree 
[1] 
 
 
Agree 
[2] 
Neither 
agree nor 
disagree 
[3] 
 
 
Disagree 
[4] 
 
Strongly 
Disagree 
[5] 
 
 
Mean 
Cuts to social services, 
benefits etc. 
51% 32% 16% 0% 2% 1.70 
People are less embarrassed 
about saying they are 
depressed 
 
38% 
 
49% 
 
5% 
 
5% 
 
3% 
 
1.86 
More people just want to 
feel better without making 
changes in their lives 
 
36% 
 
38% 
 
17% 
 
8% 
 
0% 
 
1.97 
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GPs have less time to talk 
with patients 
43% 33% 6% 9% 8% 2.06 
People are no more 
depressed than they used to 
be, but more are treated 
 
29% 
 
48% 
 
11% 
 
11% 
 
2% 
 
2.10 
Social media 
 
29% 40% 27% 3% 2% 2.10 
Other types of treatment are 
not funded or are too 
expensive 
 
36% 
 
40% 
 
6% 
 
9% 
 
8% 
 
2.13 
Drug companies have 
successfully promoted an 
illness model of depression 
 
32% 
 
35% 
 
16% 
 
16% 
 
2% 
 
2.21 
People are finding it 
difficult to come off their 
antidepressants 
 
21% 
 
36% 
 
29% 
 
14% 
 
0% 
 
2.37 
Many people don't want 
talking therapies 
16% 41% 22% 14% 6% 2.54 
More people are depressed 
these days 
13% 32% 30% 14% 11% 2.79 
Brexit 
 
6% 27% 30% 19% 17% 3.14 
Antidepressants are the best 
treatment 
0% 8% 35% 36% 21% 3.70 
       
 Far too 
high 
Slightly 
too high 
About 
right 
Slightly 
too low 
Far too 
low 
 
What is your opinion about 
the current rate of 
antidepressant prescribing 
(one in six adults in 
England) [n = 66] 
 
43% 
 
40% 
 
16% 
 
2% 
 
0% 
 
 
 
Services for people in withdrawal 
When asked ‘What services, if any, should be provided for people when they experience 
withdrawal effects from antidepressants’ 42 GPs offered 56 suggestions. Table 9 summarises 
these recommendations. All 56 who answered the question ‘Who should provide these 
services/’ ticked ‘NHS’, with 48% also endorsing ‘NGOs/voluntary sector’ and 11% ‘private 
sector’ (participants could tick more than one). 
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Table 9. Services needed for people when withdrawing from antidepressants. 
  Examples 
Counselling/ talking 
therapies/ 
psychological support 
12 Supportive psychological therapies for targeted support. 
Support and counselling. 
Written information  
 
7 More patient information on what to expect when withdrawing. 
At least an information leaflet with support from GP. 
Telephone helpline 6 A help line and website. 
A dedicated helpline based in community mental health sector 
(and/or in primary care, specifically commissioned) 
Access to pharmacist 6 Access to trained, experienced pharmacists. 
Easy access to liquid formulations to be able to make 
microscopic downward titrations with pharmacy supervision etc. 
Online 
support/information 
5 On line information and guidance. 
Online support where they can submit their side effects and 
receive tailored guidance about how to reduce safely. 
Informed GP 5 There is no reason why a GP or a primary care mental health 
worker cannot deal with this. They just need time, which is what 
we do not have.  
Ease of access to a GP with knowledge about how to manage it. 
Someone with expertise (could be the GP with information or 
access to specialist advice) 
Mental health services 4 Community mental health support. 
Competent mental health professional (and I don't mean a 
randomly named minimally experienced 'mental health support 
worker'). 
Individualised plan 4 An individual plan for the person to come off slowly with clear 
explanations as what to expect and what to do if s/he 
experiences withdrawal symptoms. 
Group support 
 
2 Patient groups 
Key worker 2 Named support worker 
 
 
Recommendations 
The GPs were asked ‘Do you have a message for Mental Health or Health Minsters about 
depression and/or its treatment?’ and 47 (71%) responded, with 69 messages. The most 
common theme was increasing mental health services (21), with specific references to 
inaccessibility of psychological/talking therapies (12) (including IAPT – 6 and CBT – 2), and 
children’s services (6). Only one GP mentioned CPNs and psychiatrists. Six GPs wanted to 
tell the Minister to tackle the social causes of depression. Five wanted increased focus on 
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social prescribing. Four wanted an overall reduction in the medicalising and medicating of 
depression and other forms of distress. Some examples are presented in Table 10. 
 
Table 10. Examples of messages for Ministers about depression and/or its treatment 
We are overtreating depression with medication instead of improving access to talking therapies 
and tackling the causative issues of social isolation, social media and poverty as well as many 
other social problems 
We are causing significant harm to our patients by continuing with the biological chemical 
imbalance model of depression and prescribing potentially harmful drugs which cause suffering in 
withdrawal and may actually contribute to chronic depression 
People need help and advice on how to improve quality of their lives eg advice re hobbies locally.  
I think every area should have updated lists of interests/hobbies for all age groups and contact 
details provided.  Thinking of isolated people, single parent families etc. 
There is still a huge shortage of MH services across the board. CAHMS is woeful in most areas , the 
waits for IAPT ridiculous , the CmHTs in crisis and so as GPs we are left trying to sort these vary 
complex patients in 10 minute appointments as well as deal with their physical health, carers and 
families.  
The erosion of continuity of care in general practice leads to poorer, more expensive health care. 
A trusted relationship with a GP who can see you repeatedly over time is one of the cheapest 
interventions and likely to be equally as effective as medication 
Social prescribing should be promoted to people before they get ill eg through schools, on the tv. 
 
Please stop medicalising everything. Not every low mood is Depression which needs to see a GP. 
Clinicians cannot solve mental health issues caused by poverty, unemployment, poor education 
etc. Please address poverty. 
Increase psychological services provision 
 
Please ensure that GPs have a real and accessible ALTERNATIVE to prescribing antidepressants.  It 
is heart breaking to feel this is all we have to offer. 
I think it’s shameful that talking therapies and social prescribing are so inaccessible, and if 
available have such long waiting lists as to render them useless. 
 
 
Finally, the GPs were asked ‘What needs to change to reduce levels of depression in society?’ 
The 44 who responded provided 62 recommendations. The most common theme was 
increasing social connectedness/reducing isolation (15), followed by reducing inequality (9), 
improving children’s wellbeing/safety (8) and improving work culture (7). See Table 11 for 
examples. 
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Table 11. Examples of responses to ‘What needs to change to reduce levels of depression in 
society?’ 
Improve social support, help reduce isolation and bring back communities. 
1. Accommodation; 2. Benefits; 3. Employment (IPS); 4. Education & training; 5. Socialisation 
support (preventing isolation) 
More social support - both within society and provision by local government/social services/NHS. 
Societal change, more inclusion, local activities, greater sense of community, 
Less shift work, more focus on importance of rest, daylight, time to prepare healthy meals, 
exercise- requiring improved/safer cycle ways towns designed around people not cars and shorter 
working days to allow time for people to look after themselves.   
Greater equity of income/wealth.  More emphasis on health and wellbeing of children and 
support for their parents. 
Less pressure in schools on results, support for young peoples services 
Less inequality, less poverty, less loneliness, more social cohesion. 
 
More work to address health inequalities, child poverty, in-work poverty, homelessness and 
alcohol/substance misuse. 
Many jobs are working people increasingly harder. Many jobs are not secure. The cost of living has 
risen much quicker than wages, putting financial strain on people. Employers expect more and 
more from employees with little reward or consideration for their well-being. It seems that these 
days people think that many problems can be fixed with tablets (I think the drug companies are to 
blame for this, and worry that if we head towards a system like America, this will get worse with 
drug advertising). Many medical problems can be helped by eating well/exercising/sleeping 
well/socialising - but these all take time and effort, something which the modern day doesn't 
seem to allow for easily. Better education in school about looking after yourself would be a start.  
 
Discussion 
A psycho-social perspective 
Some critics blame the epidemic of AD prescribing on an overly biological approach towards 
human distress adopted by psychiatry and the powerful influence of the drug companies on 
prescribers and consumers,7,28-31 often exerted via biased, industry-sponsored websites.32,33 
 
Overall, however, this small sample of GPs adopts a predominantly psycho-social perspective 
on the causes of, and solutions to, depression. Most (80%) believe that psycho-social factors 
are more important than bio-genetic factors, with ‘Child abuse/neglect’ and ‘Violence/rape in 
adulthood’ the two most endorsed of 13 specific causes, and ‘Genetic predisposition’ and 
‘Chemical Imbalance’ the two least endorsed. The most common recommendations for 
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reducing societal depression levels are: increasing social connectedness/reducing isolation, 
reducing inequality, and improving children’s wellbeing/safety. These beliefs are consistent 
with previous studies of GPs,34,35 and with the public’s causal beliefs,36,37 including people 
taking antidepressants.38,39 
 
These GPs do believe there is a role for ADs, but only for moderate/severe depression. For 
minimal/mild depression six other treatment approaches are preferred, most strongly 
psychological therapies and social prescribing. The least endorsed of 13 explanations for 
increasing prescription rates is ‘Antidepressants are the best treatment’ (with the most 
endorsed being ‘Cuts to social services, benefits, etc.’). Most (83%) think prescription rates 
are too high. All but one (98%) agreed that’ Talking therapies should be as accessible as 
pharmacological treatments’. 
 
Two in every three (67%) believe that one of the factors for ever increasing prescribing rates 
is that ‘Drug companies have successfully promoted an illness model of depression’. 
Although few (7%) believe that they are influenced by drug company salespeople 
themselves, most (82%) believe that their colleagues are influenced. (This is, however, a 
common phenomenon, exemplified by most of us believing that we are better than the 
average driver).40  Another potential explanation, not considered by our survey, is that GPs 
prescribing decisions are led by whether patients present their difficulties in terms of 
symptoms or psycho-social events.41  
 
Implementing the PHE recommendations 
This very small sample of GPs report a very wide range of beliefs about how many people 
experience withdrawal symptoms (Table 5), and about how long people need to successfully 
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come off (Table 6), indicating that, for many, these are guesses rather than evidence-based 
assertions. This is understandable given the misinformation published by NICE and other 
official bodies until very recently. One in four (24%) think that even after being on 
antidepressants for three years, no more than 10% of people will experience withdrawal 
symptoms when they try to come off. This contrasts with the 56% average rate identified (for 
all lengths of treatments combined) by the latest review.21 
 
Nearly half (45%) think that most people can ‘can come off antidepressants successfully 
within two months.’ Evidence is emerging, however, that suggests that antidepressants, like 
benzodiazepines, should usually be tapered very slowly, often over several months or longer 
(but tailored to the individual) not two to four weeks as suggested by many guidelines.42,43 
 
Less than one in three (29%) believe their ‘Knowledge about the withdrawal effects of 
antidepressants’ is ‘adequate’; and only about one in seven (14%) think their ‘Ability to 
distinguish between withdrawal effects and return of the original problem (e.g. depression)’ is 
‘adequate’. Two thirds (68%) state they would like more training on these matters, 
particularly (but not exclusively) online training about strategies for weaning patients off. 
 
There was also a clear lack of consistency in how often GPs ‘initiate discussion about when 
to come off them’. The finding that nearly one in three (32%) did so once a year or less often 
might be a focus of training. 
 
The PHE recommendation which has been the focus of this paper is just one of several aimed 
at ‘Improving support available from the healthcare system’. The range of services identified 
by our GPs in Table 9 seem important, as is their unanimous message that such services 
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should be provided by the NHS, with about half (48%) also endorsing ‘NGOs/Voluntary 
sector’. The focus on targeted psychological support during withdrawal is consistent with a 
recent systematic review on managing withdrawal from antidepressants.44 ‘ 
.   
Information given to patients 
Most (77%) GPs ticked ‘Always’ or ‘Most of the time’ when asked ‘When discussing 
possible prescribing of antidepressants, how often do you inform patients of the possibility of 
withdrawal effects when reducing or coming off?’ This is in stark contrast to the two largest 
surveys ever conducted, of over 180045 and over 140016 antidepressant recipients, in which 
less than 2% reported being told anything about withdrawal effects by the prescribing doctor. 
 
If our GPs’ reports of their own practice are accurate, rather than the result of social 
desirability, this would lend support to the possibility that our small sample did, indeed, 
differentially include GPs with a high degree of knowledge, and good practice, about, 
antidepressant withdrawal (see Limitations).  
 
Telling people about adverse effects is not only a pre-requisite for meeting the essential 
ethical principle of informed choice, it can have unexpected beneficial effects. In a large 
online survey, self-reported efficacy was independently predicted, after controlling for a 
range of other psycho-social variables, by both the amount of information about ADs offered 
by the prescriber and the perceived quality of the relationship between prescriber and 
patient.45 
 
Sources of information for GPs 
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It seems that at least as many GPs consult the British National Formulary (76%) in the 
current sample) as NICE guidelines (71%). Changes in NICE need to be paralleled by 
updates to the BNF, which currently promotes the notion that ‘Patients with a history of 
recurrent depression should receive maintenance treatment for at least 2 years’. It also states 
that the frequency of ‘withdrawal syndrome’ is ‘not known’, and that ‘withdrawal effects are 
usually mild and self-limiting, but in some cases may be severe’.46 
Limitations 
The obvious limitation to this study is the very small sample size, representing only about 
0.15% of GPs in England, and effectively none from the rest of the UK.  Under normal 
circumstances such a sample size would prohibit submission to a journal. In the current 
abnormal circumstances (COVID-19), however, with no further recruitment possible, or 
appropriate, we hoped our data, however limited, may be helpful to government officials, 
professional bodies, and researchers,47 planning for implementation of the hugely important 
PHE Report once these circumstances abate. 
 
The most likely bias resulting from the tiny sample is disproportionate inclusion of GPs with 
a particular interest in, and knowledge of, antidepressants and withdrawal therefrom. If this 
was the case (and we have no way of knowing) then the findings relating to the psycho-social 
perspective of GPs, for example, should be received with great caution. The levels of 
perceived inadequacy of knowledge and the numbers with inaccurate beliefs about incidence 
and duration of withdrawal, might be even more pronounced in a more representative sample.  
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